MedTrace Logo

Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers

NCT04821375 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-10-29

No results posted yet for this study

Summary

Pilot study to test feasibility of 6 months of bazedoxifene (BZA) plus conjugated estrogens (CE) to modulate breast MRI parameters.

Conditions

  • Increased Risk for Development of Breast Cancer

Interventions

DRUG

bazedoxifene plus conjugated estrogens

6 months of bazedoxifene (20 mg) and conjugated estrogens (0.45 mg) taken together daily.

Sponsors & Collaborators

  • Carol Fabian, MD

    lead OTHER

Principal Investigators

  • Carol J Fabian, MD · University of Kansas Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-02
Primary Completion
2024-05-20
Completion
2024-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04821375 on ClinicalTrials.gov